XIAMEN AMOYTOP BIOTECH revenue for the last year amounted to 2.10 B CNY, the most of which — 2.10 B CNY — came from its highest performing source at the moment, Recombinant Protein Drugs, Health Consulting and Medical Services, the year earlier bringing 1.52 B CNY. The greatest contribution to the revenue figure was made by China — last year it brought XIAMEN AMOYTOP BIOTECH 2.09 B CNY, and the year before that — 1.51 B CNY.